GSK updates share count and 4.05B voting rights

GSK plc (GSK) reported its share capital and voting rights position as at 31 August 2026.

Rhea-AI Filing Summary

GSK plc (GSK) reported its share capital and voting rights position as at 31 August 2026. The issued share capital consisted of 4,316,302,379 Ordinary Shares of 31¼ pence each, of which 270,881,064 shares were held in treasury.

After excluding treasury shares, the total number of voting rights in GSK was 4,045,421,315. Shareholders may use this voting-rights figure as the denominator when assessing whether they must notify interests or changes in interests under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

Key Figures

Issued share capital: 4,316,302,379 Ordinary Shares Treasury shares: 270,881,064 Ordinary Shares Total voting rights: 4,045,421,315 +2 more

5 metrics

Issued share capital 4,316,302,379 Ordinary Shares Issued share capital as at 31 August 2026

Treasury shares 270,881,064 Ordinary Shares Ordinary Shares held in Treasury as at 31 August 2026

Total voting rights 4,045,421,315 Total number of voting rights in GSK as at 31 August 2026

Ordinary Share nominal value 31¼ pence per share Nominal value of each GSK Ordinary Share

Company registration number 3888792 Registered in England & Wales

Key Terms

Treasury Shares, Total voting rights, Disclosure Guidance and Transparency Rule 5.6.1R, Foreign private issuer

4 terms

Treasury Shares financial

"of which 270,881,064 Ordinary Shares were held in Treasury"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Total voting rights financial

"Therefore, the total number of voting rights in the Company is 4,045,421,315"

The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.

Disclosure Guidance and Transparency Rule 5.6.1R regulatory

"In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R"

Foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the total number of voting rights in GSK (GSK) as of 31 August 2026?

As of 31 August 2026, GSK reported a total of 4,045,421,315 voting rights. This figure reflects issued Ordinary Shares excluding those held in treasury and is the denominator shareholders should use for UK disclosure threshold calculations.

How many shares has GSK (GSK) issued as of 31 August 2026?

As of 31 August 2026, GSK’s issued share capital consisted of 4,316,302,379 Ordinary Shares of 31¼ pence each. This total includes shares held in treasury, which do not carry voting rights.

How many GSK (GSK) shares are held in treasury?

GSK reported that 270,881,064 Ordinary Shares were held in treasury as at 31 August 2026. Treasury shares are not counted towards voting rights, so they are excluded from the total voting-rights figure.

Why did GSK (GSK) publish this total voting rights announcement?

GSK published the total voting rights information in conformity with the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rule 5.6.1R, enabling shareholders to determine if they must notify interests or changes in interests in the company.

Who signed the September 2026 GSK (GSK) total voting rights report?

The report was signed on behalf of GSK by Victoria Whyte, described as Company Secretary and Authorised Signatory for and on behalf of GSK plc, dated 1 September 2026 in London.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 12:26 PM EDT Accepted by SEC EDGAR 09/01/2026 - 12:26 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 1 September 2026, London UK

Total Voting Rights

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 31 August 2026 consisted of 4,316,302,379 shares of 31 ¼ pence each ('Ordinary Shares'), of which 270,881,064 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,045,421,315. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

1 September 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: September 01, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc